| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 04/20/2000 | WO2000022138A1 Genetic factor of s. meliloti usda 1170 containing nodulation efficiency factor |
| 04/20/2000 | WO2000022137A2 Selectively replicating viral vectors |
| 04/20/2000 | WO2000022136A2 Recombinant e1a deleted adenoviral vectors |
| 04/20/2000 | WO2000022135A1 Helicobacter pylori vaccine |
| 04/20/2000 | WO2000022134A2 Test kit for diagnosis of borrelia infection and novel borrelia antigens for the development of vaccines |
| 04/20/2000 | WO2000022133A1 Fungal genes required for normal growth and development |
| 04/20/2000 | WO2000022132A2 Nucleic acids that control reproductive development in plants |
| 04/20/2000 | WO2000022131A2 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/20/2000 | WO2000022130A2 Metastatic breast and colon cancer regulated genes |
| 04/20/2000 | WO2000022129A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 04/20/2000 | WO2000022128A1 Protein conjugates containing multimers of green fluorescent protein |
| 04/20/2000 | WO2000022127A1 Compositions and methods based upon p35, an isoform of p53 |
| 04/20/2000 | WO2000022126A1 Follistatin-related protein zfsta2 |
| 04/20/2000 | WO2000022125A2 6-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 04/20/2000 | WO2000022124A2 Methods and compositions to induce antitumor response |
| 04/20/2000 | WO2000022123A1 Novel protein war-1 and gene thereof |
| 04/20/2000 | WO2000022122A2 Genes, proteins and biallelic markers related to central nervous system disease |
| 04/20/2000 | WO2000022121A2 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 04/20/2000 | WO2000022120A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | WO2000022119A1 METHOD FOR OBTAINING ACTIVE β-NGF |
| 04/20/2000 | WO2000022118A2 Non-desensitizing ampa-receptors |
| 04/20/2000 | WO2000022117A1 Tumor protein |
| 04/20/2000 | WO2000022116A1 Human mdg1 gene (cbfawb10) |
| 04/20/2000 | WO2000022115A2 Assays for identifying functional alterations in the p53 tumor suppressor |
| 04/20/2000 | WO2000022114A1 PRODUCTION OF ssDNA $i(IN VIVO) |
| 04/20/2000 | WO2000022113A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 04/20/2000 | WO2000022112A1 Stabilized bioactive peptides and methods of identification, synthesis and use |
| 04/20/2000 | WO2000022111A1 Method for generating diversity |
| 04/20/2000 | WO2000022110A2 Targeted proteolysis by recruitment to ubiquitin protein ligases |
| 04/20/2000 | WO2000022107A1 Method for amplifying foreign gene |
| 04/20/2000 | WO2000022100A2 Arthropod protein disulfide isomerases |
| 04/20/2000 | WO2000022099A1 Materials and methods for the modification of plant lignin content |
| 04/20/2000 | WO2000022098A1 Porcine oocytes with improved developmental competence |
| 04/20/2000 | WO2000022095A2 Method and apparatus for direct in vivo gene transfer by electrotransfection |
| 04/20/2000 | WO2000022092A2 Materials and methods for the modification of plant cell wall polysaccharides |
| 04/20/2000 | WO2000022001A2 A potassium channel of the erg family |
| 04/20/2000 | WO2000022000A1 Methods for the production of antibodies to specific regions of cyclosporine and cyclosporine metabolites |
| 04/20/2000 | WO2000021999A1 Novel g protein-coupled receptors |
| 04/20/2000 | WO2000021997A1 D-1 like dopamine receptor activity modifying protein |
| 04/20/2000 | WO2000021996A2 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | WO2000021995A1 Treatment of inflammatory disease |
| 04/20/2000 | WO2000021994A1 Human ptd011 gene (tpaahe09) |
| 04/20/2000 | WO2000021993A1 Human ptd010 gene (tpaaag12) |
| 04/20/2000 | WO2000021992A1 A human fk506 binding protein (fkbp) |
| 04/20/2000 | WO2000021991A1 SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| 04/20/2000 | WO2000021990A1 SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| 04/20/2000 | WO2000021989A1 Decorin binding proteins dbp a and b and genes encoding them |
| 04/20/2000 | WO2000021988A2 Human ankyrin family protein |
| 04/20/2000 | WO2000021987A2 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 04/20/2000 | WO2000021986A2 Matrix-remodeling genes |
| 04/20/2000 | WO2000021978A2 Laminin 5, 13 and 14 and uses thereof |
| 04/20/2000 | WO2000021976A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 04/20/2000 | WO2000021974A1 Nucleotide compounds including a rigid linker |
| 04/20/2000 | WO2000021973A1 Isolation method for nucleic acid and apparatus |
| 04/20/2000 | WO2000021574A2 Site-directed dual pegylation of proteins |
| 04/20/2000 | WO2000021559A2 Blocking factor b to treat complement-mediated immune disease |
| 04/20/2000 | WO2000021557A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | WO2000021553A2 Method of regulating smn gene expression |
| 04/20/2000 | WO2000021551A1 Isolated peptides which bind to hla-b35 molecules |
| 04/20/2000 | WO2000021544A1 Ups (undecaprenyl diphosphate synthase) |
| 04/20/2000 | WO2000021362A1 VIABLE PrP (PRION PROTEIN) TRANSGENIC ANIMALS AND METHODS OF USE |
| 04/20/2000 | WO2000014247A3 Agents and methods for modifying the glutamine metabolism in plants, especially in sugar beet |
| 04/20/2000 | WO2000006775A9 Exon deletion antisense drug design and therapy |
| 04/20/2000 | WO2000006605A9 Heterominibodies |
| 04/20/2000 | WO2000005586A3 Rna helicases modulating translation termination |
| 04/20/2000 | WO2000004196A3 Cis acting nucleic acid elements and methods of use |
| 04/20/2000 | WO2000004162A3 Genes encoding sulfate assimilation proteins |
| 04/20/2000 | WO2000004155A3 Compositions and methods for enhancing disease resistance in plants |
| 04/20/2000 | WO2000004145A3 Myotilin, an actin-organizing protein |
| 04/20/2000 | WO2000004052A3 Soluble derivatives of anti-angiogenic peptides |
| 04/20/2000 | WO2000004040A3 Constitutive disease resistance gene (cdr1), and methods of use thereof |
| 04/20/2000 | WO2000003687A3 Potassium channel polypeptide and polynucleotide compositions |
| 04/20/2000 | WO2000003004A3 Presenilin 2 specific ribozyme |
| 04/20/2000 | WO2000001832A3 Inducible promoters |
| 04/20/2000 | WO2000001814A3 Non-human mammal wherein a gene coding for an scuz-protein can be de-activated in a time-specific or tissue-specific manner |
| 04/20/2000 | WO2000001713A9 Diacylglycerol acyl transferase proteins |
| 04/20/2000 | WO2000001440A3 Methods for treating neurological injuries and disorders |
| 04/20/2000 | WO2000000622A3 Human oxidoreductase proteins |
| 04/20/2000 | WO2000000585A3 MAIZE CYTOCHROME P450 MONOOXYGENASE cDNA (CYP71C3v2) |
| 04/20/2000 | WO2000000515A3 A CHEMOKINE RECEPTOR OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN |
| 04/20/2000 | WO2000000506A3 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 04/20/2000 | WO1999067407A3 Transgenetic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 04/20/2000 | WO1999067398A3 Overexpression of phytase genes in yeast systems |
| 04/20/2000 | WO1999066065A3 Proteasomal activity |
| 04/20/2000 | WO1999066037A3 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/20/2000 | WO1999066032A3 Cells, genetically modified with optical marker |
| 04/20/2000 | WO1999065712A3 Glycosulfopeptides and methods of synthesis and use thereof |
| 04/20/2000 | WO1999064626A8 Probes used for genetic profiling |
| 04/20/2000 | WO1999064461A3 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 04/20/2000 | WO1999063086B1 Insulin-like growth factor binding protein-3 variants |
| 04/20/2000 | WO1999063068A9 Phenotype modifying genetic sequences |
| 04/20/2000 | WO1999061469A3 Prostate growth-associated membrane proteins |
| 04/20/2000 | WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene |
| 04/20/2000 | WO1999058947A9 Modulation of molecular interaction sites on rna and other biomolecules |
| 04/20/2000 | WO1999058658A3 Expression vectors for stimulating an immune response and methods of using the same |
| 04/20/2000 | WO1999057266A3 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 04/20/2000 | WO1999055861A3 Fibroblast growth factor mutein compositions and methods of use therefor |
| 04/20/2000 | WO1999054463A3 Human k+ ion channel and therapeutic applications thereof |
| 04/20/2000 | WO1999053078A3 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| 04/20/2000 | WO1999053062A3 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |